GlassScriptPhysician profile
Ryan T Boone
NPI 1902891476
$2,110.70
in general payments reported to CMS, 2019-2025
21 companies · $644 in 2025
The $644 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $65.77 · 2021: $459 · 2022: $184 · 2023: $151 · 2024: $300 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.17 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $415.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $294.21 | 2019-2025 | Dupixent |
| Genzyme Corporation | $227.75 | 2021-2025 | |
| Stryker Corporation | $202.23 | 2019-2025 | Scopis Ent, Xpress Loprofile |
| Glaxosmithkline, LLC. | $191.57 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $122.13 | 2025 | Inspire |
| Neurent Medical Limited | $120.39 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Arbor Pharmaceuticals, INC. | $79.23 | 2019 | |
| Genentech USA, INC. | $58.55 | 2019 | |
| Alk-Abello, INC | $52.31 | 2021-2022 | |
| Kaleo, INC. | $51.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $45.75 | 2019-2021 | |
| Aerin Medical INC. | $42.14 | 2025 | |
| Abbvie INC. | $39.10 | 2021 | |
| Olympus America INC. | $35.41 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $34.00 | 2025 | |
| Medtronic, INC. | $28.24 | 2021 | |
| Smith+Nephew, INC. | $25.00 | 2022 | |
| Acclarent, INC | $20.02 | 2019 | |
| Merck Sharp & Dohme LLC | $13.87 | 2023 | |
| Mylan Pharmaceuticals INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.